Overview

Immuno-oncology is aimed at destroying cancer cells by stimulating the patient's immune system without affecting healthy tissues, with the goal of delivering long-lasting responses and cure. This process is tightly regulated by interactions between receptors on immune cells that influence the immune response against cancer cells. 
 
LeadArtis has generated an array of novel drug candidates, including a tumor-targeted costimulatory MT simultaneously targeting a clinically validated tumor-associated antigen (TAA) on cancer cells and T cell costimulatory Tumor Necrosis Factor Receptors (TNFR). A follow-up candidate is a T cell-recruiting bispecific antibody with the ATTACK configuration. 
 
These Trimerbodies allow us to fine tune the potency of the T cell activation and cell killing, potentially improving the tolerability of tumor immunotherapy. We have demonstrated highly effective and well-tolerated killing of target cells in a variety of assays.

Latest News

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021

...

Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...

Leadartis to present on May 26th, 2021 its business to the 17th Annual Anglonordic Life Science Conference
20-05-2021

Anglonordic is a great event to meet quality investors and companies - it is very well run and...